How Voyager™ DSLT and Valeda™ work together to capture the two largest age-related eye disease markets — from the same patient demographic.
Glaucoma and dry AMD are the two most prevalent age-related eye diseases, affecting the same patient demographic. A practice that treats both captures the full opportunity.
Without Voyager DSLT, your glaucoma patients are referred out for SLT. Without Valeda, your dry AMD patients hear 'there's nothing we can do' and seek care elsewhere. Every referral is lost revenue and a weakened patient relationship.
Both devices keep patients in-house. Voyager DSLT enables any ophthalmologist to perform SLT — no gonio lens, no specialist training. Valeda transforms the dry AMD conversation from 'watch and wait' to 'let's start treatment today.'
Practices report retaining 30-40% more patients who would otherwise be referred out or lost to attrition.
A 68-year-old patient presents with both open-angle glaucoma and early dry AMD — an extremely common comorbidity in the 60+ population. Today, most practices can only address one condition and refer for the other.
With both devices, the same patient receives Voyager DSLT for their glaucoma (2.4 seconds, one visit) and Valeda for their dry AMD (< 5 min/eye, 9 sessions). Same practice, same staff, same infrastructure.
Each dual-diagnosis patient generates ~$235 (Voyager DSLT) + ~$2,700 (Valeda course) = ~$2,935 in combined procedure revenue — from a single patient.
A single device purchase carries risk — what if volume doesn't meet projections? The fixed cost of one device must be justified by one revenue stream.
Two devices share the same exam lane infrastructure, staff training model, and patient demographic. The marginal cost of adding the second device is lower than the first because the practice workflow is already adapted.
Practices with both devices report faster ROI on each individual device because the shared infrastructure reduces per-procedure overhead.
Optometrists and primary care physicians need somewhere to send their aging patients with eye disease. They prefer a single, trusted referral destination.
A practice offering both Voyager DSLT and Valeda becomes the go-to referral center for the two most common age-related eye diseases. Optometrists can send both their glaucoma and dry AMD patients to one practice.
Early adopters of both technologies report 2-3x increase in optometric referrals within the first year — the 'innovation halo' effect.
Most ophthalmic procedures are one-time events. Revenue is unpredictable and depends on new patient acquisition.
Valeda requires maintenance treatments every 4 months — creating a predictable, compounding revenue stream. Voyager DSLT is repeatable as needed. Together, they create a recurring revenue model that grows with your patient base.
A practice treating just 10 Valeda patients/month generates ~$324K in annual recurring revenue from maintenance alone — on top of Voyager DSLT procedure revenue.
Three scenarios based on weekly procedure volume. All figures assume standard Medicare reimbursement and typical Valeda course pricing.
Six key talking points for positioning Voyager DSLT and Valeda as a unified Alcon technology platform rather than standalone products.
Voyager DSLT addresses the anterior segment (trabecular meshwork for glaucoma), while Valeda treats the posterior segment (retina for dry AMD). Together, they cover the two most prevalent age-related eye diseases.
Both glaucoma and dry AMD primarily affect patients over 60. A practice investing in both devices captures a larger share of the same aging patient population, maximizing chair time and patient lifetime value.
Both devices are office-based, non-invasive, and delegatable to qualified health professionals. They share the same practice infrastructure — no OR time, no sedation, minimal consumables.
Voyager DSLT generates revenue per procedure with established CPT 65855 reimbursement. Valeda creates a recurring revenue stream with maintenance treatments every 4 months. Together, they build predictable, compounding practice income.
Offering both first-of-their-kind technologies positions the practice as a cutting-edge center of excellence. This drives referrals, attracts new patients, and strengthens the practice's competitive moat.
Both products are backed by Alcon — the world's largest eye care company. A dual-product relationship deepens the partnership, unlocks potential volume incentives, and positions the practice for future Alcon innovations.
Tailor your dual-product pitch based on the practice structure. Click each profile to see specific talking points for Voyager DSLT and Valeda.
Access the full training guide for each product — including clinical evidence, competitive intelligence, quizzes, flashcards, and role-play practice.